Bipolar disorder treatment for Delray Beach — the diagnosis primary care misses.

RECO Integrated Psychiatry is a Delray Beach outpatient specialty clinic — steps off Atlantic Avenue and minutes from Pineapple Grove — focused on adults with bipolar I, bipolar II, and bipolar spectrum presentations. The clinicians here run lithium, lamotrigine, valproate, and second-generation antipsychotic protocols with full monitoring built in, and take diagnostic accuracy seriously enough to defer medication changes when the history is still ambiguous. In network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS.

RECO Integrated Psychiatry practices in downtown Delray Beach, a short walk from Atlantic Avenue and the ocean. For adults living in Pineapple Grove, Lake Ida, Tropic Isle, the Beach District, or Osceola Park, specialty psychiatric care for bipolar disorder is available inside the same neighborhood without the disruption of a residential program. The clinic is structured around adult outpatient psychiatry — diagnostic assessment, longitudinal medication management, and coordination with therapy — for the specific clinical needs of bipolar I, bipolar II, and bipolar spectrum presentations.

Bipolar I, bipolar II, and bipolar spectrum: getting the diagnosis right

The single most consequential decision in bipolar care is diagnostic. Bipolar I requires at least one manic episode — seven days of elevated or irritable mood with functional impairment, hospitalization, or psychosis. Bipolar II requires a hypomanic episode of at least four days plus a full major depressive episode. Bipolar spectrum captures presentations that carry the biology of bipolar disorder — clear cyclicity, family history, early onset, antidepressant-induced hypomania, mixed features — without meeting full DSM criteria. Cyclothymia and other specified bipolar and related disorder live in this territory.

The distinction is not academic. Bipolar I responds to mood stabilizer plus second-generation antipsychotic combinations, with lithium and valproate carrying the strongest evidence in mania. Bipolar II depression responds to lamotrigine and quetiapine and less predictably to lithium monotherapy. Bipolar spectrum presentations require conservative antidepressant use, mood stabilizer cover, and close monitoring for switch. Miscategorizing bipolar depression as unipolar and reaching for an SSRI without a stabilizer is the single most common reason adults with bipolar disorder cycle through years of failed treatment.

The diagnostic evaluation uses the Mood Disorder Questionnaire (MDQ), the Hypomania Checklist (HCL-32), a structured hypomania history with collateral input where appropriate, and prospective mood charting over the first several visits. The bipolar disorder treatment pathway begins with a ninety-minute intake that is diagnostic first and prescriptive second.

Lithium: the treatment RECO takes seriously when others don’t

Lithium remains the most effective long-term mood stabilizer in bipolar disorder and the only psychiatric medication with a robust, replicated anti-suicide signal. Meta-analyses across decades support its role in maintenance for bipolar I, with strong evidence in mania and moderate evidence in bipolar depression. It is underprescribed in the United States relative to its evidence base, largely because the monitoring is inconvenient for clinicians who see patients briefly.

The protocol treats monitoring as built-in rather than optional. Baseline workup includes TSH, creatinine, calcium, CBC, and pregnancy testing where relevant. Target serum level is 0.6 to 1.0 mEq/L for maintenance, with higher levels tolerated in acute mania. Trough levels are drawn twelve hours after the last dose, quarterly during initiation and every six months once stable. Thyroid and renal function are checked at least annually, and weight, blood pressure, and metabolic parameters are tracked on the same schedule.

For clients who tolerate lithium, the durability of response justifies the monitoring burden. The clinicians here are comfortable managing drug interactions, dose adjustments during illness or NSAID use, and the counseling around hydration, sodium, and pregnancy planning that make long-term lithium safe.

Second-generation antipsychotics: choosing by phase, not by habit

Several second-generation antipsychotics carry FDA approval in bipolar disorder, and the choice among them is driven by illness phase, prior response, and tolerability. Quetiapine has approvals across bipolar depression, mania, and maintenance and is often the first choice when depression is the presenting phase. Lurasidone is approved for bipolar I depression and carries a favorable metabolic profile. Cariprazine is approved for both mania and bipolar depression. Aripiprazole and risperidone are approved for mania, and aripiprazole for maintenance as well. Olanzapine and the olanzapine-fluoxetine combination are approved for bipolar depression and mania but carry the heaviest metabolic burden.

Metabolic monitoring — fasting glucose or HbA1c, lipids, weight, blood pressure, and waist circumference — is standard on any second-generation antipsychotic. The protocol schedules these at baseline, three months, and annually, with more frequent checks on olanzapine or in clients with prediabetes or dyslipidemia. Movement side effects, including akathisia, parkinsonism, and tardive dyskinesia, are assessed at each visit using the AIMS.

The clinical judgment sits in the sequencing. A client with bipolar II depression and low metabolic risk may start on lurasidone or quetiapine. A client with bipolar I mania and prior aripiprazole response returns to aripiprazole. A client failing lithium monotherapy on the depression pole often benefits from adding quetiapine or lurasidone rather than switching stabilizers.

Lamotrigine, valproate, and the anticonvulsant options

Lamotrigine has the strongest evidence for maintenance treatment where depression is the predominant pole and is the treatment of choice for many clients with bipolar II. The titration is deliberately slow — 25 mg daily for two weeks, 50 mg daily for two weeks, 100 mg for one week, then 200 mg — because rash and rare Stevens-Johnson syndrome are dose- and titration-rate-dependent. Any rash prompts immediate discontinuation and clinical assessment. Valproate levels, oral contraceptives, and pregnancy each alter lamotrigine kinetics and require dose adjustment.

Valproate is effective in acute mania and mixed states, with target serum levels of 50 to 125 mcg/mL. Monitoring includes LFTs, CBC with platelets, and levels at baseline, during titration, and every six months once stable. Valproate is teratogenic and requires explicit counseling and contraception planning in clients of reproductive age; it is generally avoided as a first-line agent in this population. Carbamazepine and oxcarbazepine remain second-line options with their own interaction profiles and monitoring requirements.

What to expect on the first visit

The initial evaluation runs ninety minutes. It covers a longitudinal mood history — first depressive episode, first hypomanic or manic episode, cyclicity, seasonal pattern, response to prior medications, family history of bipolar disorder or completed suicide, and any history of antidepressant-induced hypomania. Sleep, substance use, and medical contributors such as thyroid disease, steroid exposure, and stimulant use are covered explicitly.

Clients complete the MDQ, HCL-32, PHQ-9, GAD-7, and a brief substance use screen before or during the visit. Where the diagnosis is genuinely uncertain, the clinician may defer initiating or changing medication until a second visit with collateral information or prospective mood charting. Accurate diagnosis is what makes the rest of the treatment work.

Insurance and admissions from Delray Beach

RECO Integrated Psychiatry is in network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and Blue Cross Blue Shield. Verification of benefits is completed before the first visit so the client receives a written estimate of cost-share in advance. For clients using out-of-network benefits, itemized superbills are provided for reimbursement.

The Delray Beach office is a zero-mile drive from anywhere inside the city — most clients arrive in under ten minutes from Pineapple Grove, Lake Ida, Tropic Isle, the Beach District, or Osceola Park. Street parking is available on 4th Avenue and adjacent side streets off Atlantic. Telepsychiatry follow-ups are offered to stable clients after the in-person intake, and are commonly used for medication check-ins between labs drawn locally.

Serving residents of: Pineapple Grove, Lake Ida, Tropic Isle, Beach District, Osceola Park.